This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -12.50% and 121.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Fate Therapeutics (FATE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics (FATE) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -30.43% and -10.54%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
by Zacks Equity Research
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -29.17% and -72.98%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
by Neena Mishra
2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -32.14% and -19.26%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
3 Stocks Under $10 That Surged Today
by Benjamin Rains
Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on earnings estimate revisions in order to find winning stocks. However, we also always seek to cover stocks, big and small, that are making noteworthy moves.
Fate Therapeutics (FATE) Jumps: Stock Rises 5.7%
by Zacks Equity Research
The shares of Fate Therapeutics (FATE) rose nearly 6% yesterday.
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?
by Zacks Equity Research
Investors in Fate Therapeutics (FATE) need to pay close attention to the stock based on moves in the options market lately.
Surging Earnings Estimates Signal Good News for Fate Therapeutics (FATE)
by Zacks Equity Research
Fate Therapeutics (FATE) could be an interesting play for investors as it sees solid activity on the earnings estimate revision.
Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
by Zacks Equity Research
Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include AINV, BLDP, CBAY, FATE and OCLR.
Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
by Zacks Equity Research
Fate Therapeutics, Inc. (FATE) has been on the move lately as the stock has risen by 43.4% in the past four weeks, and it is currently trading well above its 20-Day SMA
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
by Zacks Equity Research
Fate Therapeutics, Inc. (FATE) has been on the move lately as the stock has risen by 14.8% in the past four weeks, and it is currently trading well above its 20-Day SMA